U.S. Food and Drug Administration, Center for Drug Evaluation and Research
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Erhalten Sie aktuelle Informationen zu Krebsbehandlungen, Zulassungen und Sicherheitsupdates in dieser informativen Podcast-Serie über Onkologie und Arzneimittelentwicklung.
FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients
3 mins • Jan 17, 2025
Charts
- 173Decreased by 56
- 198Decreased by 31
- 198NEW
- 183Decreased by 135
- 173Decreased by 159
Neueste Folgen

Jan 17, 2025
FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients
3 mins

Dec 30, 2024
FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy
3 mins

Nov 18, 2024
FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma
3 mins

Nov 14, 2024
FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma
4 mins

Aug 16, 2024
FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer
5 mins

Sprache
Englisch
Land
Vereinigte Staaten
Website
Feed
Aktualisierung anfordern
Aktualisierungen können einige Minuten dauern.